Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track DERM with free AI briefings, catalyst countdowns, and dilution alerts.

DERM · Journey Medical Corp

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$22.3M Cash on Hand
25.9mo Cash Runway
Follow DERM by email Get an email when DERM reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about DERM, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Glycopyrronium Topical Wipes Hyperhidrosis Phase 3 · NCT02530294 Completed
DFD-29 Papulopustular Rosacea Phase 3 · NCT05343455 Completed
Glycopyrronium cloth, 2.4% Palmar Hyperhidrosis Phase 2 · NCT03880266 Completed
Dose 2 of glycopyrronium, 3.75% QD Hyperhidrosis Phase 2 · NCT02129660 Completed
Dose 2 of glycopyrrolate, 3.0% QD Hyperhidrosis Phase 2 · NCT02129660 Completed
Dose 1 of glycopyrronium, 2.5% QD Hyperhidrosis Phase 2 · NCT02129660 Completed
Dose 1 of glycopyrrolate, 2.0% QD Hyperhidrosis Phase 2 · NCT02129660 Completed
Topical Minocycline Foam FXFM244 Confluent and Reticulated Papillomatosis (CARP) Early Phase 1 · NCT07462702 Not yet recruiting

Also used in these trials (approved or third-party drugs, not DERM's own candidates): Doxycycline, Glycopyrrolate, Minocycline Hydrochloride.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

DERM holds $22.3M in cash and short-term investments (as of Sep 30, 2026) and burns about $2.6M/quarter from operations, an estimated runway of 25.9 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 10 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when DERM files for a raise →

Get the full DERM picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for DERM and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.